Mrna-4157/v940, an investigational personalized mrna cancer vaccine, in combination with keytruda(r) (pembrolizumab), receives prime scheme designation from the european medicines agency for adjuvant treatment of patients with high-risk stage iii/iv melanoma following complete resection

Designation based on positive data from phase 2b keynote-942/mrna-4157-p201 trial and unmet need for additional therapeutic options for certain types of melanoma cambridge, ma and rahway, nj / accesswire / april 6, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and merck (nyse:mrk), known as msd outside of the united states and canada, today announced that mrna-4157/v940, an investigational personalized mrna cancer vaccine, in combination with keytruda, merck's anti-pd-1 therapy, has been granted priority medicines (prime) scheme designation by the european medicines agency (ema) for the adjuvant treatment of patients with high-risk stage iii/iv melanoma following complete resection. the ema granted prime scheme designation based on positive data from the phase 2b keynote-942/mrna-4157-p201 trial.
MRNA Ratings Summary
MRNA Quant Ranking